The Washington Post
Business Context

McKesson’s opioid tax disclosure

Updated Feb 12, 2021 at 12:11 PM EST

The drug distributor said in its quarterly SEC filing in February 2021 it expects to pay $8.1 billion into the nationwide opioid settlement. McKesson says this amount will be $6.7 billion after taxes, suggesting it expects a total tax benefit of $1.4 billion. The company also said $497 million in tax benefits were “uncertain” because of the “uncertainty in connection with the deductibility of opioid related litigation and claims.”

Read the full story here.


Click here to download if the document isn't visible or legible.

The drug distributor said in its quarterly SEC filing in February 2021 it expects to pay $8.1 billion into the nationwide opioid settlement. McKesson says this amount will be $6.7 billion after taxes, suggesting it expects a total tax benefit of $1.4 billion. The company also said $497 million in tax benefits were “uncertain” because of the “uncertainty in connection with the deductibility of opioid related litigation and claims.”